199 results about "Cancer recurrence" patented technology

The present invention provides gene sets the expression of which is important in the diagnosis and / or prognosis of cancer, in particular of breast cancer.

The subject disclosure presents systems and computer-implemented methods for assessing a risk of cancer recurrence in a patient based on a holistic integration of large amounts of prognostic information for said patient into a single comparative prognostic dataset. A risk classification system may be trained using the large amounts of information from a cohort of training slides from several patients, along with survival data for said patients. For example, a machine-learning-based binary classifier in the risk classification system may be trained using a set of granular image features computed from a plurality of slides corresponding to several cancer patients whose survival information is known and input into the system. The trained classifier may be used to classify image features from one or more test patients into a low-risk or high-risk group.

A gene expression signature of colon cancer, microarrays including them and methods of using the colon gene expression signature are provided. The gene expression signature is especially useful for determining the prognosis of a patient diagnosed with colon cancer, such as stage II colon cancer. The gene signature described herein is also useful for determining effectiveness of surgical resection with or without adjuvant chemotherapy, and determining possibility of cancer recurrence in patients with colon cancer.

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

The present invention provides methods of screening for, detecting or diagnosing prostate cancer in a subject by determining the level of prostate specific antigen (PSA), complexed PSA (cPSA), free PSA, B-PSA, PRO-PSA or HK2 in a biological sample from the subject and correcting this level for free / bioavailable serum testosterone, total testosterone or sex hormone binding globulin. The present invention further relates to identifying a subject at risk for developing prostate cancer or for determining the effectiveness of anti-cancer therapy in a subject having prostate cancer, or for detecting cancer recurrence by determining the level of prostate specific antigen (PSA), complexed PSA (cPSA), free PSA, B-PSA, PRO-PSA or HK2 in a biological sample from the subject and correcting this level for free or bioavailable serum testosterone, total testosterone or a testosterone bound protein, including but not limited to sex hormone binding globulin.

The invention provides methods of estimating the likelihood of lung cancer recurrence in a subject, including those afflicted with NSCLC. The methods of the invention are useful for developing a therapeutic treatment plan to prevent cancer recurrence for subjects deemed to be at high risk, and withholding treatments from those subjects deemed to be at low risk. The invention also provides methods of generating and using metagene-based prediction tree models for estimating the likelihood of lung cancer recurrence. The invention also provides reagents, such as DNA microarrays, software and computer systems useful for estimating cancer recurrence, and provides methods of conducting a diagnostic business for the prediction of cancer recurrence.

The present invention provides a composition comprising a nicotine-containing material and an anti-cancer agent usable in the treatment and / or prevention or reduction of the risk of cancer and precancerous conditions as well as for preventing or reducing the risk of cancer recurrence. Furthermore, a composition comprising a nicotine-containing material and an anti-inflammatory agent usable in the treatment and / or prevention or reduction of the risk of inflammation, is provided. The nicotine containing composition can also include both an anti-cancer agent and an anti-inflammatory agent A device for administering the composition of the present invention to subjects can be a cigarette, smoking pipe, smokeless tobacco, electronic cigarette, transdermal patch or the like.

The present invention is directed to sensitive and specific methods and kits for the detection of prostate cancer in a patient. The invention uses RT-PCR to detect the expression or change in expression of PSA in epithelial cells enriched from whole blood. The methods and kits on the invention represent a a significant improvement over previous methods of CaP diagnosis. According to one embodiment, prostate epithelial cells are isolated from blood and the RNA subjected to RT-PCR. The resulting cDNA is subjected to traditional PCR amplification with primers able to distinguish between the genomic copy of the gene and the cDNA copy resulting from CaP gene expression. This method provides an assay which is more sensitive, specific and reproducible as compared to conventional methods. Results disclosed herein demonstrate a correlation between the presence of PSA-expressing prostate epithelial cells with cancer recurrence which provides a diagnostic tool for the early detection of prostate disease.

The present invention provides gene sets the expression of which is important in the diagnosis and / or prognosis of cancer, in particular of breast cancer.

Methods and immunoassays for the determination of fatty acid synthase (FAS) expression in patients having or suspected of having a proliferative disorder, especially prostate cancer, are disclosed. The sensitive method and assay detect the level of expression of FAS in a biological sample using antibodies that are highly specific for FAS. The method and assay can be used to monitor the progression of cancer, and / or to predict the efficacy of certain treatments or the likelihood of recurrence of the cancer.

The invention is directed to a product comprising a nicotine-containing material and an anti-cancer agent. The product is applicable in the treatment and / or prevention of cancer and precancerous conditions as well as for preventing cancer recurrence.

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to cancer. In particular, the disclosure includes the identities of genes that are expressed in correlation with tumor grade. The levels of gene expression are disclosed as a molecular index for determining tumor grade in a patient and predicting clinical outcome, and so prognosis, for the patient. The molecular grading of cancer may optionally be used in combination with a second molecular index for diagnosing cancer and its prognosis. The disclosure further includes methods for predicting cancer recurrence, and / or predicting occurrence of metastatic cancer. For diagnosis or prognosis, the disclosure further includes methods for determining or selecting the treatment of cancer based upon the likelihood of life expectancy, cancer recurrence, and / or cancer metastasis.

The invention relates to a transurethral intravesical operation instrument system for non-muscle invasive bladder cancer. The system comprises an endoscope with multiple passages, a) a tail end-bendable operation instrument with a bendable joint and / or b) a tail end-bendable operation instrument with a pre-bent pipe structure. According to the system, the tail end-bendable operation instrument with the bendable joint and the tail end-bendable operation instrument with the pre-bent pipe structure are independently matched with the endoscope with the multiple passages for use or the two operation instruments are simultaneously matched with the endoscope with the multiple passages for use, so that operation instrument tail ends in various shapes can be obtained, an encircling operating angle is formed, fine operation is facilitated, and an operated part can be observed in real time; compared with the prior art, the system has the characteristics of fine operation, all-angle operation, no blind zones, complete excision, convenience in the mastering of the excision depth, humanized operation and the like, the cure rate of non-muscle invasive bladder cancer is expected to be increased, operation complications are reduced, and the cancer recurrence rate is lowered.

An N1-cyclic amine-N5-substituted phenyl biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs.; Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.

The invention relates to a cancer recurrence prediction system based on a multi-dimensional Gaussian distribution Bayesian classification, which comprises a preprocessing module, a training module anda Bayesian classifier; the pre-processing module performs data cleaning on the training set and generates a class vector data set; the training module first calculates the first probability of two class attributes, and then divides the data attribute into a class data attribute set which is closely related to the class attribute and a class II data attribute set which is sparse with the class attribute association degree by using the pearson correlation coefficient, two types of data attribute sets are respectively used for calculating a corresponding probability by using a multi-dimensionalGaussian distribution and a one-dimensional Gaussian distribution; the Bayesian classifier combines both the probability of the two and the first probability of the class together as the probability of the data belonging to each class, and the classification test result of the cancer is judged accordingly. The cancer recurrence prediction system based on multi-dimensional Gaussian distribution Bayesian classification improves the predictive accuracy of the recurrence of the cancer.

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and / or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and / or cancer metastasis.

The invention provides a series of new multi-fluorine-substituted pyrazolopyrimidine type compounds or salts. The compounds are Bruton's tyrosine kinase (BTK) inhibitors, and can have better kinase inhibition selectivity and pharmacokinetic property. The invention discloses a preparation method of the compounds and also discloses medicine combination containing the compounds with other target medicine compositions or other medicines. The optimized medicine combination has a synergistic effect, can greatly inhibit the existence of tumors as compared with a single target medicine, and can completely eliminate certain tumors. The optimized medicine combination can greatly treat the medicine resistance of the tumors and prevent the cancer recurrence as compared with the single target medicine, and the treatment period is shorter. The invention further relates to combined compounds and medicine preparations using the compounds as active elements, and at a lower dosage, the compounds are safer and have the curative effect of the synergistic effect. The invention further comprises methods for treating and inhibiting the autoimmune diseases or symptoms, heterogeneous immune diseases or symptoms, inflammatory diseases and cancer or symptoms by using the compounds and preparations of the compounds.

An N1-cyclic amine-N5-substituted phenyl biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.

The preset invention relates to use of antipsychotic phenothiazine derivative for eliminating cancer stem cells (CSCs) and / or preventing a cancer. The invention also provides a pharmaceutical composition for treating a cancer, and / or preventing or delaying cancer recurrence comprising trifluoperazine and an anti-cancer drug, such as gefitinib or cisplatin.

An N1-cyclic amine-N5-substituted phenyl biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.

Methods for the ex vivo generation of cells of the innate (NKT cells and NK cells) and adaptive (T cells) immune systems for use in adoptive cell transfer (ACT) are provided. The NKT cells render T cells resistant to immune suppression (e.g. they are resistant to the effects of myeloid-derived suppressor cells (MDSCs)). The method involves culturing disease-primed immune cells (obtained from a cancer patient or from a patient with an infectious disease) with i) byrostatin and ionomycin (B / I) to activate and differentiate the cells; followed by sequentially culturing the cells with a) a combination of IL-7 and IL-15 and then b) IL-2, to further differentiate the cells and to render them immune resistant. The resistant immune cells are used to treat and prevent cancer and infectious diseases.

The present invention is drawn to methods of assessing colorectal cancer prognosis by examining the expression of particular genes disregulated in this disease state. Subjects exhibiting disregulation in one or more of these genes will have a higher risk of cancer recurrence and death.

The invention discloses a gene group evaluating breast cancer molecule typing and a detection kit thereof. The gene group evaluating breast cancer molecule typing is a gene group composed of 216 genes. The invention also discloses the detection kit for the gene group evaluating breast cancer molecule typing. The detection kit comprises a primer capable of detecting the genes in the gene group for evaluating breast cancer molecule typing and cancer recurrence risk. An Illumina second-generation sequencing technology DASL-Seq is employed for detecting expression spectrum of cancer tissue, and on the above basis, breast cancer cases of Chinese women are divided into five molecule typing: 1) luminal type A, 2) luminal type B, 3) HER2 enrichment type, 4) basal cell type and 5) normal-cell like type, and propagation and immunization index are combined for calculating recurrence risk and pridicting recurrence possibility in 10 years, and thus individual treatment on breast cancer is guided.

The invention relates to a biomarker and detection method for detecting the risk of cancer recurrence, wherein the biomarker for detecting the risk of cancer recurrence comprises at least one of the following genes: SLCO2A1, CGNL1, SUPV3L1, TATDN2, MGAT4B, VAV2, SLC25A33, MCCC1, ASNS, CASKIN1, DNMT3B, AURKA, OIP5, CTHRC1 and GOLGA7B. The biomarker for detecting the risk of cancer recurrence, provided by the invention, has an advantage of effectively predicting the recurrence risk of cancers such as prostate cancer and the like.

Methods and tools for assessing the prognosis for patients following treatment of primary tumors are provided. The methods involve identifying immune-related genetic markers whose differential expression patterns at tumor lesions are indicative of either tumor recurrence or recurrence-free survival. The methods and tools of the invention assist physicians by providing objective decision-making tools for planning patient treatment protocols.

A N1-cyclic amine-N5-substituted biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.

The present invention relates to a cancer stem cell-targeting carbon nano-tube-salinomycin drug delivery system, which comprises carbon nano-tubes, drug molecules adsorbed to the carbon nano-tubes, a modification material, and a targeting molecule. The present invention further relates to a preparation method and uses of the carbon nano-tube targeting drug delivery system. According to the present invention, the novel strategy is provided for selective targeting and effective clearing of cancer stem cells, and cancer recurrence and metastasis caused by cancer stem cells can be fundamentally prevented.

The invention discloses a biopolymer pharmaceutical composition for tumor therapy. The biopolymer pharmaceutical composition comprises a first component and a third component, wherein the first component is alginate; the alginate can form porous gel together with calcium ions in vivo, and the alginate is one or more of sodium alginate, potassium alginate and ammonium alginate; and the third component is an immune adjuvant. The biopolymer pharmaceutical composition can generate a synergistic anti-cancer effect, and reduces side effects, the cancer metastasis probability, and the cancer recurrence probability.

A method of determining likelihood of acquiring drug resistance of a tumor or cancerous cells, cancer metastasis, cancer recurrence, or decreased life expectancy, comprising measuring the level of MUC1 or MUC1-associated factor expressed in the cancerous cells or tumor.

The present invention discloses a breast cancer treatment traditional Chinese medicine, and belongs to the field of traditional Chinese medicines. The breast cancer treatment traditional Chinese medicine is prepared from the following raw materials: 20 g of trichosanthes kirilowii maxim, 20 g of milkvetch root, 20 g of common selfheal spike, 20 g of oyster, 15 g of bupleurum chinense, 15 g of scutellaria baicalensis georgi, 15 g of curcuma aromatica salisb., 15 g of angelica, 15 g of immature tangerine fruit, 15 g of white peony root, 15 g of balloonflower root, 15 g of szechwan lovage rhizome, 10 g of bulbus fritillariae cirrhosae, 10 g of dandelion, 10 g of stiff silkworm, 10 g of ginseng, 10 g of fructus aurantii, 10 g of magnolia officinalis, 10 g of angelica archang lica, 10 g of saposhnikovia divaricata, 10 g of lindera aggregata, 10 g of pangolin, 6 g of tangerine peel, 6 g of akabia stem, and 6 g of licorice root. The breast cancer treatment traditional Chinese medicine has effects of healthy energy supporting, qi reinforcing, blood nourishing, spleen strengthening, liver soothing, blood stasis dissipating, detoxication, good chemotherapy reaction alleviating and cancer recurrence and metastasis prevention so as to increase the comprehensive treatment effect and achieve the purposes of patient symptom improvement and complete cancer cell killing.